Related Experiment Video
Updated: Aug 10, 2025

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
Mushroom-Derived Compounds as Metabolic Modulators in Cancer
Bhoomika Dowaraka-Persad1,2, Vidushi Shradha Neergheen1
1Biopharmaceutical Unit, Centre for Biomedical and Biomaterials Research (CBBR), University of Mauritius, Réduit 80837, Mauritius.
Abstract:
Cancer is responsible for lifelong disability and decreased quality of life. Cancer-associated changes in metabolism, in particular carbohydrate, lipid, and protein, offer a new paradigm of metabolic hits. Hence, targeting the latter, as well as related cross-linked signalling pathways, can reverse the malignant phenotype of transformed cells. The systemic toxicity and pharmacokinetic limitations of existing drugs prompt the discovery of multi-targeted and safe compounds from natural products. Mushrooms possess biological activities relevant to disease-fighting and to the prevention of cancer. They have a long-standing tradition of use in ethnomedicine and have been included as an adjunct therapy during and after oncological care. Mushroom-derived compounds have also been reported to target the key signature of cancer cells in in vitro and in vivo studies. The identification of metabolic pathways whose inhibition selectively affects cancer cells appears as an interesting approach to halting cell proliferation. For instance, panepoxydone exerted protective mechanisms against breast cancer initiation and progression by suppressing lactate dehydrogenase A expression levels and reinducing lactate dehydrogenase B expression levels. This further led to the accumulation of pyruvate, the activation of the electron transport chain, and increased levels of reactive oxygen species, which eventually triggered mitochondrial apoptosis in the breast cancer cells. Furthermore, the inhibition of hexokinase 2 by neoalbaconol induced selective cytotoxicity against nasopharyngeal carcinoma cell lines, and these effects were also observed in mouse models. Finally, GL22 inhibited hepatic tumour growth by downregulating the mRNA levels of fatty acid-binding proteins and blocking fatty acid transport and impairing cardiolipin biosynthesis. The present review, therefore, will highlight how the metabolites isolated from mushrooms can target potential biomarkers in metabolic reprogramming.
Insights
Mushroom compounds offer a natural approach to combat cancer by targeting metabolic reprogramming. These natural products show promise in selectively inhibiting cancer cell growth and halting proliferation.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Cancer significantly impacts quality of life, with metabolic alterations in carbohydrates, lipids, and proteins being key drivers.
- Existing cancer drugs face limitations in systemic toxicity and pharmacokinetics, necessitating the search for safer, multi-targeted therapies.
- Mushrooms have a history in ethnomedicine and cancer care, with their compounds demonstrating anti-cancer properties in preclinical studies.
Purpose of the Study:
- To review how mushroom-derived metabolites can target metabolic reprogramming biomarkers in cancer.
- To explore the potential of natural compounds from mushrooms as a therapeutic strategy against cancer.
- To highlight selective anti-cancer mechanisms of mushroom compounds on metabolic pathways.
Main Methods:
- Literature review of studies on mushroom-derived compounds and their effects on cancer metabolism.
- Analysis of in vitro and in vivo studies demonstrating the anti-cancer activities of specific mushroom metabolites.
- Examination of identified molecular targets and pathways affected by these compounds.
Main Results:
- Panepoxydone demonstrated protective effects against breast cancer by modulating lactate dehydrogenase A and B, leading to apoptosis.
- Neoalbaconol selectively induced cytotoxicity in nasopharyngeal carcinoma by inhibiting hexokinase 2.
- GL22 inhibited hepatic tumor growth by downregulating fatty acid-binding proteins and affecting fatty acid transport and cardiolipin biosynthesis.
Conclusions:
- Mushroom metabolites represent a promising source of novel anti-cancer agents targeting key metabolic pathways.
- Targeting metabolic reprogramming offers a selective approach to halting cancer cell proliferation with potentially reduced toxicity.
- Further research into mushroom-derived compounds could lead to new adjunct therapies for oncological care.
More Related Videos
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Mitogens and the Cell Cycle
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

